Literature DB >> 31090040

Antithrombin as a marker of severe acute hepatitis B.

Simona Arientová1, O Beran2, P Chalupa2,3, M Kořínková3, M Holub2.   

Abstract

BACKGROUND: Acute hepatitis B (AHB) can run a severe course, which sometimes leads to a fulminant disease with acute liver failure (ALF). Pro-coagulation factors are well-established markers of AHB severity, but less is known about the levels of anti-coagulation parameters in AHB.
METHODS: In this study, we demonstrate that antithrombin (AT) plasma levels were associated with AHB severity in 161 patients.
RESULTS: Nine (6%) patients had severe AHB (i.e. international normalized ratio [INR] ≥ 1.6 and total bilirubin ≥ 10 mg/dL). Coagulopathy (i.e. INR > 1.2 and/or AT < 80%) was observed in 65 (40%) AHB patients on admission. Low initial plasma AT levels (i.e. < 80%) were observed in 56 (35%) patients. In all, plasma AT levels decreased in 91 (57%) patients during their hospital stay. Both baseline and nadir AT levels were significantly lower in severe than in mild and moderate AHB. Moreover, the concentration of AT negatively correlated with INR, aspartate aminotransferase, and total and conjugated bilirubin levels. Interestingly, nadir AT levels positively correlated with the duration of hospitalization.
CONCLUSIONS: These results indicate that plasma AT levels can be used as an additional marker of AHB severity.

Entities:  

Keywords:  Acute hepatitis B; Antithrombin; Coagulopathy; Severity

Mesh:

Substances:

Year:  2019        PMID: 31090040     DOI: 10.1007/s12664-019-00948-5

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  29 in total

1.  Administration of antithrombin III attenuates posthepatectomy liver failure in hepatocellular carcinoma.

Authors:  Shintaro Kuroda; Hirotaka Tashiro; Tsuyoshi Kobayashi; Masakazu Hashimoto; Yoshihiro Mikuriya; Hideki Ohdan
Journal:  Dig Surg       Date:  2015-03-28       Impact factor: 2.588

Review 2.  Acute liver failure.

Authors:  R D Hughes; J Wendon; A E Gimson
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

4.  Tenofovir treatment of the severe acute hepatitis B.

Authors:  Fernando Casals-Seoane; Beatriz Arberas-Díez; Luisa García-Buey
Journal:  Rev Esp Enferm Dig       Date:  2013-01       Impact factor: 2.086

5.  Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischemia/warm reperfusion injury.

Authors:  Sevil Isik; Pars Tuncyurek; Neslihan Inci Zengin; Ali Eba Demirbag; Fuat Atalay; Sezai Yilmaz; Taner Orug
Journal:  Hepatogastroenterology       Date:  2012 Mar-Apr

Review 6.  Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?

Authors:  Hans L Tillmann; Kalliopi Zachou; George N Dalekos
Journal:  Liver Int       Date:  2011-11-15       Impact factor: 5.828

7.  Hepatitis B: the virus and disease.

Authors:  T Jake Liang
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 8.  An update on hepatitis B, D, and E viruses.

Authors:  Jennifer Price
Journal:  Top Antivir Med       Date:  2014-01

9.  Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B.

Authors:  Jurgen Gerada; Elaine Borg; Denise Formosa; Rosalie Magro; James Pocock
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-06-03       Impact factor: 2.576

10.  Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands.

Authors:  Susan Hahné; Robin van Houdt; Femke Koedijk; Marijn van Ballegooijen; Jeroen Cremer; Sylvia Bruisten; Roel Coutinho; Hein Boot
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.